Rheumatoid Arthritis Trial, Recruiting NCT06779123 Sponsor: taVNS AB Condition: Rheumatoid Arthritis
Back to Rheumatoid Arthritis

Rheumatoid Arthritis Trial, Recruiting

NCT06779123
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are over 18 years of age at the time of signing the consent form
  • People with active rheumatoid arthritis, measured by a disease activity score above 3.2, with at least 4 tender and 4 swollen joints (out of 28 joints assessed)
  • People whose rheumatoid arthritis did not respond well enough to, stopped responding to, or who could not tolerate at least one approved biologic or targeted medication for rheumatoid arthritis, including a type of drug known as JAK inhibitors
  • People who have been on a stable dose of steroid medications for at least 2 weeks, or stable dose of conventional disease-modifying arthritis drugs for at least 4 weeks, before the screening visit

Who may not be able to join:

  • People who have had a surgical procedure that cuts or removes part of the vagus nerve (a nerve running from the brain to the abdomen)
  • People who have had part or all of their spleen removed
  • People who experience repeated episodes of fainting caused by a sudden drop in heart rate or blood pressure
  • People with a psychiatric illness that is untreated or not well managed
  • People with a significantly weakened immune system due to an underlying health condition
  • People who have had a stroke or similar brain blood vessel event in the past
  • People with a serious heart or cardiovascular condition
  • People with fibromyalgia that is not well controlled
  • People who are pregnant (the trial requires sexually active participants to use a reliable form of contraception, or to be at least 2 years past menopause)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 6 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Ulf Andersson, Professor, taVNS AB

Phone: +46 12370000

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
taVNS AB
Registry
ClinicalTrials.gov
Start date
21 March 2025
Est. completion
15 October 2026

Where this trial is recruiting

🇸🇪 Sweden

Primary endpoints

ACR 20 response

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov